Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Arcadia Biosciences, Inc. (RKDA)
|
Add to portfolio |
|
|
|
| Price: |
$1.39
| | Metrics |
| OS: |
1.11
|
M
| |
|
|
| Market cap: |
$1.54
|
M
| |
|
|
|
Net cash:
|
$13.5
|
M
| |
$12.16
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($16.2)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 6.8 | 8.0 | 1.2 | 1.5 | 4.0 | 3.2 | 5.4 | 7.0 |
| Revenue growth | -15.6% | 587.3% | -20.2% | -63.6% | 26.3% | -41.1% | -22.5% | 7.8% |
| Cost of goods sold | 8.7 | 5.2 | -20.7 | 0.0 | 0.0 | 0.9 | 0.9 | 2.0 |
| Gross profit | -1.9 | 2.8 | 21.8 | 1.5 | 4.0 | 2.3 | 4.5 | 5.0 |
| Gross margin | -28.4% | 35.3% | 1867.8% | 100.0% | 100.0% | 71.9% | 83.5% | 71.4% |
| Selling, general and administrative | -0.2 | 15.6 | 13.6 | 11.6 | 10.7 | 12.3 | 11.1 | 10.1 |
| Research and development | | | 7.1 | 6.1 | 7.4 | 8.7 | 9.0 | 10.0 |
| EBITA | -15.0 | -3.9 | -19.4 | -16.9 | -14.3 | -18.6 | -15.6 | -16.1 |
| EBITA margin | -221.0% | -48.2% | -1657.9% | -1152.3% | -355.6% | -584.1% | -287.5% | -230.4% |
| Amortization of intangibles | 0.1 | 0.0 | | | | | | |
| EBIT | -15.1 | -3.9 | -19.4 | -16.9 | -14.3 | -18.6 | -15.6 | -16.1 |
| EBIT margin | -222.7% | -48.6% | -1657.9% | -1152.3% | -355.6% | -584.1% | -287.5% | -230.4% |
| Pre-tax income | -16.1 | -6.2 | -28.9 | -13.5 | -15.7 | -19.6 | -17.9 | -18.1 |
| Income taxes | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 |
| Tax rate | | 2.0% | | | | | | |
| Net income | -14.7 | -4.7 | -28.8 | -13.5 | -15.7 | -19.6 | -20.7 | -22.1 |
| Net margin | -216.2% | -57.9% | -2464.1% | -920.8% | -390.1% | -615.6% | -382.8% | -316.2% |
| |
| Diluted EPS | ($0.69) | ($0.47) | ($4.53) | ($3.58) | ($7.28) | ($8.85) | ($0.73) | ($10.71) |
| Shares outstanding (diluted) | 21.3 | 10.0 | 6.4 | 3.8 | 2.2 | 2.2 | 28.6 | 2.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|